Tilray Beverages Announces Campaign to Raise Awareness for Men’s Health
June 14, 2024 07:00 ET
|
Tilray Brands, Inc.
With this campaign and the partnerships involved, Tilray hopes to encourage more men to take an active role in their health and well-being.
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress
June 14, 2024 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, June 14, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...
TScan Therapeutics Announces Updates to its Board of Directors
June 14, 2024 07:00 ET
|
TScan Therapeutics, Inc.
Garry A. Nicholson, an experienced executive with regulatory and commercial expertise, joins the Board of Directors Timothy Barberich retires as Chair; Stephen Biggar, M.D., Ph.D. assumes the role...
Generation Bio to Present at the 2024 TD Cowen Genetic Medicines & RNA Summit
June 14, 2024 06:59 ET
|
Generation Bio Co.
CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases,...
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
June 14, 2024 06:00 ET
|
Shattuck Labs, Inc.
– Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall...
The Ensign Group, Inc. Declares Quarterly Dividend of $0.06 Per Share
June 14, 2024 06:00 ET
|
The Ensign Group, Inc.
SAN JUAN CAPISTRANO, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled...
Greenwich LifeSciences Announces $2.5 Million Private Placement
June 14, 2024 06:00 ET
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company" or "Greenwich"), a clinical-stage biopharmaceutical company focused on its Phase III...
La SOGC demande un cadre national pour la collecte de données sur la mortalité maternelle
June 14, 2024 05:59 ET
|
La Société des obstétriciens et gynécologues du Canada
EDMONTON, Alberta, 14 juin 2024 (GLOBE NEWSWIRE) -- La mort de toute femme suite à une grossesse ou à un accouchement est une tragédie, et pourtant, le Canada ne fait pas assez pour prendre les...
SOGC Calls for National Framework for Maternal Mortality Data Collection
June 14, 2024 05:59 ET
|
The Society of Obstetricians and Gynaecologists of Canada
EDMONTON, Alberta, June 14, 2024 (GLOBE NEWSWIRE) -- The death of any one woman as a result of pregnancy or childbirth is too many, yet Canada is not doing enough to take steps that could prevent...
Updated Phase 2 CAPTIVATE study results demonstrate sustained clinical benefit of fixed-duration IMBRUVICA® (ibrutinib) plus venetoclax as first-line treatment for patients with chronic lymphocytic leukaemia, including those with high-risk disease
June 14, 2024 03:13 ET
|
Janssen Cilag International NV
At 5 years, 67 percent of patients were progression-free, with overall survival at 96 percent for all treated patients 1 BEERSE, BELGIUM, June 14, 2024 (GLOBE NEWSWIRE) --...